Autologous Fat Graft Combined With Botulinum Toxin Injection for Breast Augmentation in Poland Syndrome: A Prospective and Comparative Study
Wang N., Wei S., Qiang S., Wang J., Zeng X., Zhang Z.
Prospective Study with a reported sample of 20, published in J Cosmet Dermatol (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- J Cosmet Dermatol (2025)
- Reported sample size
- 20
- Source database
- Europe PMC
- PMID
- 39950221
- PMCID
- PMC11826372
- DOI
- 10.1111/jocd.70070
Abstract (original English)
Background Poland syndrome is a rare congenital condition characterized by unilateral breast deformity. Autologous fat transplantation has emerged as the preferred treatment due to its minimal invasiveness, rapid recovery, absence of rejection reactions, and potential for multiple surgeries to enhance postoperative outcomes. Previous animal studies have shown that botulinum toxin significantly improves fat retention rates following fat transplantation. Therefore, we aim to initiate a clinical study to investigate the effects of botulinum toxin on human fat transplantation. Objective This prospective comparative clinical study aims to evaluate the impact of combining botulinum toxin with autologous fat grafting on fat retention rates in patients with Poland syndrome. Method From October 2017 to December 2023, we enrolled 20 Poland syndrome patients, assigning them to an experimental group receiving fat and botulinum toxin for breast augmentation and a control group undergoing standard autologous fat grafting. Postoperative fat retention rates were compared, and outcomes were assessed using the Breast-Q score, alongside baseline patient data. Results There were no significant differences in baseline data between the two groups. At 3 and 6 months postoperatively, the fat retention rate in the experimental group was significantly higher than that in the control group. Regarding Bre
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.